Rocket Reports Positive Clinical Safety Data from Three RP-A501 Patients

Rocket Pharmaceuticals reported that its RP-A501 gene therapy was well-tolerated with no significant safety concerns observed in three treated patients, leading the company to engage actively with the FDA on the next steps for the Phase 2 pivotal trial.